Back to Search
Start Over
Evaluation of the Efficacy and Safety of the Conversion From a Calcineurin Inhibitor to an Everolimus-Based Therapy in Maintenance Renal Transplant Patients
- Source :
-
Transplantation Proceedings . Sep2007, Vol. 39 Issue 7, p2148-2150. 3p. - Publication Year :
- 2007
-
Abstract
- Abstract: Everolimus has recently been introduced into clinical practice with promising perspectives due to its efficacy, lack of nephrotoxicity, and antitumor effects. Experience in clinical trials associated with low-dose cyclosporine showed good results, but there is almost no experience in calcineurin inhibitor (CNI) elimination learning it as the primary immunosuppressant. We describe our experience in a series of 78 stable renal transplant patients who were switched to Everolimus with complete and quick elimination of the CNI: the procedure of conversion, pharmacokinetic results after conversion, evolution of renal parameters (renal function, proteinuria, and others), and safety data (acute rejection and adverse events). An initial dose of 3 mg/d was adequate to obtain the recommended trough levels between 5 and 10 ng/mL. Our results demonstrated that conversion to Everolimus was a simple, safe procedure that must be considered in patients CNI toxicity, especially those with malignant neoplasms and progressive deterioration of renal function due to chronic allograft nephropathy. [Copyright &y& Elsevier]
- Subjects :
- *CHEMICAL inhibitors
*ANTINEOPLASTIC agents
*CYCLOSPORINE
*KIDNEY transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 00411345
- Volume :
- 39
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Transplantation Proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 26679733
- Full Text :
- https://doi.org/10.1016/j.transproceed.2007.06.030